(MENAFN - ProactiveInvestors - Australia) Resonance Health's (ASX: RHT) non-invasive, MRI-based service for the measurement of liver iron overload, FerriScan, will become a service that is eligible for insurance reimbursement for some patients in the U.S.
Health insurer, Medical Mutual of Ohio, has notified members that it considers FerriScan medically necessary and eligible for reimbursement for patients falling within defined criteria for treatment across a broad range of indications, on an annual basis.
Prior authorisation is not required before FerriScan can be performed.
This is a very positive outcome for FerriScan and patients with iron overload in the U.S., and follows two positive insurance coverage policies announced in 2012.
Blue Cross Blue Shield Massachusetts and Kaiser Permanente, two of the largest insurance payers, advised that coverage may be provided for FerriScan when a patient's clinical circumstances require it, provided prior authorisation is received.
Resonance Health is actively expanding the availability of FerriScan in the U.S. to further assist in gaining approvals for reimbursement by medical insurers and making FerriScan more accessible to patients.